Efficacy of Salvia officinalis extract on the prevention of insulin resistance in euglycemic patients with polycystic ovary syndrome: A double-blinded placebo-controlled clinical trial

Authors Amini, Leila; Mojab, Faraz; Jahanfar, Shayesteh; Sepidarkish, Mahdi; Raoofi, Zahra; Maleki-Hajiagha, Arezoo

Journal COMPLEMENTARY THERAPIES IN MEDICINE , JAN 2020,:48

DOI 10.1016/j.ctim.2019.102245 PubMed 31987228

Abstract Objectives: At the present study, we aimed at evaluating the effect of Salvia officinalis (S. officinalis) extract on anthropometric indices and insulin resistance markers in Polycystic Ovary Syndrome (PCOS) patients.Design and setting: This was a randomized, triple-blinded, controlled trial performed in gynecology hospitals affiliated to Iran University of Medical Sciences.Participants: Sixty PCOS patients diagnosed according to Rotterdam criteria.Interventions: Consumption of the 330 mg oral S. officinalis extract or placebo capsules daily for eight weeks.Main outcome measures: Body mass index (BMI), waist to hip ratio (WHR), blood pressure, homoeostatic model assessment-insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI).Results: Results showed a statistically significant decrease in the BMI (P = 0.001) in S. officinalis group, but, there were no significant differences between the two groups for WHR (P = 0.164). Although we failed to find a significant effect of S. officinalis extract on systolic blood pressure (P = 0.283) but using a multivariate model showed a significant difference between two groups regarding diastolic blood pressure (P = 0.025). Also, the consumption of S. officinalis extract, compared to the placebo, resulted in a significant decrease in Insulin levels (P < 0.001), and HOMA-IR (P < 0.001). As well as, S. officinalis extract supplementation resulted in a greater increase in QUICKI (P < 0.001) compared with placebo groups.Conclusion: S. officinalis extract at a dose of 330 mg/day could decrease BMI and systolic blood pressure, and it could enhance insulin resistance markers in euglycemic PCOS patients.